Articles tagged with Metastasis
Researchers at the University of Basel have developed a novel differentiation therapy that converts breast cancer cells into fat cells, impeding the formation of metastases in mice. The therapy combines two active substances, Rosiglitazone and Trametinib, to suppress tumor growth and spread.
Basel researchers identified a substance that prevents the formation of metastases by dissociating circulating tumor cell clusters and reversing epigenetic changes. This approach targets key aspects of metastasis seeding, including proliferation and tissue-forming capabilities.
Researchers discover a potential therapy that can disrupt the recruitment of myeloid cells by cancerous tumors, boosting the function of disease-fighting M1 type of myeloid cells. This approach shows great promise in reducing tumor growth and promoting a microenvironment where T cells can attack cancer.
Researchers at Thomas Jefferson University discovered a compound from Christmas berry primrose plants can inhibit uveal melanoma growth, offering potential new treatments for patients. The compound, FR900359, works by blocking mutated G proteins that promote cancer growth.
A comprehensive study reveals that p62 protein controls multiple factors involved in melanoma metastasis, indicating a coordinated process. The research also identifies FERMT2 as a marker for poor patient prognosis.
Researchers discovered that ovarian cancer cells colonize the omentum after being caught in DNA 'webs' extruded by immune cells. Inhibiting NET formation reduces metastasis in mice, suggesting a new approach to limit ovarian cancer spread. This study provides insights into improving ovarian cancer treatment.
A new assay can analyze small amounts of material to estimate metastatic risk, enhancing prostate cancer evaluation. The Next-Generation Copy Number Alteration (NG-CNA) assay is a targeted amplification sequencing technique that can process samples faster and decrease the cost per sample.
A multigene test used in breast cancer treatment helps doctors decide on chemotherapy, improving prognosis and reducing unnecessary treatments. The study found that patients with high-risk tumors had a five-fold increased risk of metastases and lower disease-free survival rates without chemotherapy.
Researchers have engineered sensors to monitor multiple signaling pathways driving tumor metastasis, enabling the prediction of a tumor cell's potential to spread. The development of Fluorescence Resonance Energy Transfer (FRET) biosensors has the potential to transform cancer cell biology and inform personalized treatment strategies.
Researchers at the University of Tokyo have discovered that blocking a specific molecule can prevent cancer cells from spreading. The study found that inhibiting tissue type plasminogen activator (tPA) blocked melanoma growth and metastasis in mice. This breakthrough offers new possibilities for cancer therapy, potentially improving ou...
Researchers have found a potential Achilles' heel in micrometastasis that could be targeted with medications to reduce the risk of full-blown metastasis. Blocking calcium transfer through gap junctions and mTOR pathway results in cancer cell death or growth inhibition.
Researchers have discovered that metastatic cancer cells follow a Lévy walk movement pattern, like sharks searching for food, which aids in their rapid spread and direction. The team was able to reprogram this behavior using chemical inhibitors, changing it back to more typical diffusive motion
A recent study published in the British Journal of Cancer found a positive association between type 2 diabetes and an increased risk of colorectal cancer (CRC) in men, with a moderately higher risk observed. In contrast, the association was weaker and not statistically significant for women. The study followed up over 87,000 women and ...
Breast cancer cells can become invasive by changing their identity through a process called epithelial-mesenchymal transition (EMT). A newly identified protein, CXADR, plays a crucial role in this process. Reintroducing CXADR into breast cancer cells can change their behavior and repress invasive properties.
Researchers at CNIO have linked the protein MASTL to a type of inherited thrombocytopenia, which may lead to breakthroughs in cancer metastasis research. They discovered that manipulating other enzymes could potentially reverse the defect and explored its therapeutic potential.
A randomized phase III trial found that avoiding the hippocampal region during whole-brain radiotherapy significantly reduces the risk of cognitive decline. The study results have far-reaching implications for brain tumor treatment, offering a safer alternative to traditional whole-brain radiation therapy.
The NRG Oncology clinical trial BR001 found that SBRT is safe for patients with 2 metastases or 3-4 metastases in specific locations, including peripheral lung and abdomen/pelvic. The study showed zero protocol-defined dose-limiting toxicities across evaluable anatomic locations.
A new immunotherapy combination shows durable clinical benefits in patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer, with 60% objective response rate and 84% of patients experiencing tumour shrinkage. The treatment is also well-tolerated, with manageable side effects.
A large comparison study found that radiotherapy to the prostate improved failure-free survival but not overall survival in men with newly diagnosed metastatic prostate cancer and a low burden of disease. The treatment was well-tolerated, with only modest side effects.
A large study found that drugs approved for women's breast cancer are also effective and well-tolerated in men. Men with metastatic breast cancer received similar treatments to women, including hormonal therapy and chemotherapy, with similar outcomes.
Atezolizumab, an antibody targeting PD-L1, improved survival in metastatic triple negative breast cancer patients by 20%, particularly those with PD-L1 positive tumors. The combination therapy also reduced disease worsening and death risk by 38% in PD-L1 positive subgroup
A new statistical method estimates the short- and long-term risk of recurrence for hormone receptor-positive and HR-negative breast cancers in US women. The study found that while HR-positive breast cancer has a lower risk of progression to metastatic disease soon after diagnosis, the risk persists for several years.
Neutrophils isolated from bone marrow of mouse models and patients with early stage tumors exhibit increased spontaneous migration to tissues and promote tumor cell seeding. These neutrophils lack immunosuppressive characteristics, but display potent ability to spontaneously migrate and facilitate metastasis.
Researchers at Mount Sinai have discovered a new way to determine whether breast cancer cells are dormant or soon to turn deadly. Patients with high levels of the NR2F1 protein in their bone marrow are less likely to develop metastatic cancer, allowing for more targeted treatment and improved survival rates.
A new report reveals a protein, deltaNp63, that directs myeloid-derived immunosuppressor cells (MDSCs) to the primary tumor and metastatic sites, promoting tumor growth and metastasis. Blocking deltaNp63 or MDSCs reduced tumor growth and metastasis in a mouse model of triple-negative breast cancer.
Patients with metastatic non-small cell lung cancer (NSCLC) treated at academic centers had higher 2-year survival rates than those treated at community-based centers. The study found significant differences in survival outcomes based on facility type, histology, and molecular profile.
A new study suggests targeting collagen XIII could suppress breast cancer metastasis by enhancing anoikis resistance in cancer cells. Researchers found that collagen XIII expression is significantly higher in cancerous human breast tissue and necessary for metastasis in mouse models.
Researchers at Cold Spring Harbor Laboratory found that sustained lung inflammation can awaken dormant breast and prostate cancer cells, leading to metastasis. A new antibody approach may block this signaling pathway, preventing cancer recurrence.
Researchers at UC Riverside have discovered a way to target migrating cancer cells, responsible for tumor metastases, using novel agents 135H11 and 135H12. These potent agents can block EphA2, an oncogene that spreads cancer, preventing cell migration and degradation.
Researchers discovered that driver gene mutations are remarkably similar across different metastases from the same patient, offering hope for successful targeted therapies. This finding suggests that single biopsies can capture essential information for therapeutic decision-making.
Scientists at the Medical University of South Carolina discovered that over-expression of VRK1 actually slows down cancer cell migration and invasion, but enables cells to form colonies under 3D conditions. High levels of VRK1 are associated with aggressive breast cancers and poor prognoses in patients with metastatic breast cancer.
Phase 1 and phase 2 clinical trials of entrectinib in ROS1-positive non-small cell lung cancer demonstrated a response rate of 77.4 percent and median duration of response of 24.6 months. Entrectinib also showed competitive results in patients with brain metastases and poor prognosis
Researchers at UCLA have created a quick and effective mechanism to measure how circulating tumor cells perform functions that drive disease, such as producing proteins that degrade tissue. The new approach enables scientists to understand how tumor cells act, rather than just what they are made from.
A new study identified 'signposts' on cancer cells that can help the immune system recognize and kill them, potentially leading to higher recovery rates. The findings suggest a highly personalized approach to immunotherapy could improve treatment outcomes.
Scientists from the University of Luxembourg have identified a molecular mechanism responsible for colon cancer cell spread and metastasis. A small molecule cluster, miR-371~373, was found to regulate colon cancer metastasis in aggressive, fast-growing cancer cells. Reactivation of this cluster slowed down metastatic cell growth.
Researchers found that rapidly spreading ovarian cancer cells recruit CAFs to accelerate cancer proliferation and spread by enhancing energy sources. Blocking glycogen mobilization could be a therapeutic strategy for reducing tumor dissemination.
A study found that common mutations drive the spread of cancer in individual patients, suggesting a key understanding of how cancers metastasize. The research also identified passenger mutations that are less likely to play a critical role in cancer development.
A new study analyzing 76 untreated metastases from 20 patients found that different metastatic lesions share the same driver gene mutations. The findings suggest that a biopsy of a single metastatic lesion could provide sufficient information for treatment decisions.
Researchers have discovered a specific protein, FABP5, that promotes processes associated with cancer aggressiveness, including cell growth, invasiveness, survival, and inflammation. Understanding the molecular pathways of this protein could lead to finding more effective therapeutic targets for prostate and breast cancers.
Researchers aim to develop a blood test to detect and track metastatic melanoma by analyzing circulating tumor DNA in the bloodstream, promising a more precise, individualized, sensitive, and quantifiable approach than current imaging tests.
Researchers discovered a previously unseen 'ecosystem' in advanced breast cancer, where primary tumors emit signals to halt secondary tumor growth. The study found that activating the immune response can freeze secondary cancers, offering new hope for living with advanced breast cancer.
Researchers found that inflammatory response triggered by primary breast cancer prevents tumor cells from growing in distant organs. Inhibitors of interleukin-1β, such as canakinumab, are being tested in clinical trials for potential benefits in preventing metastatic growth.
A clinical trial found that combination immunotherapy reduced melanoma brain metastases by 26% in 94 patients. The treatment, combining checkpoint inhibitors ipilimumab and nivolumab, also showed durable responses with 59.5% of patients remaining progression-free at nine months.
A University of Colorado Cancer Center study reveals that inhibiting the action of lysosomes can efficiently kill metastatic cancer cells. Researchers found that the level of a protein called ID4 predicts which cancer patients will benefit most from treatment with chloroquine.
The EMBRACA trial shows that talazoparib provides a significant clinical benefit to patients with metastatic breast cancer and BRCA mutations. The study found that talazoparib improved progression-free survival, quality-of-life measures, and overall response rates compared to chemotherapy.
A new study suggests that cancer treatment should be viewed as a game where physicians can exploit their knowledge of the cancer's evolutionary dynamics to develop flexible strategic treatment plans. By continuously adjusting drugs and doses, physicians can delay or prevent cancer progression caused by resistance.
A team of researchers has confirmed that healthy tumor hybrid cells contribute to metastasis by forming spontaneously in live animals. Gene expression profiles show a mix of genes from both cell types, aiding metastatic cells in survival and potential groundwork for other tumor cells.
Researchers investigate how a group of cells breaks off from a colony, leading to large-scale metastasis. Mechanical engineer Amit Pathak aims to understand the mechanisms behind disease pathways and fundamental cell behavior.
Researchers developed a molecular probe to detect cancer stem cells in their native environment. The AlDeSense probe illuminates these cells, allowing them to be identified, tracked, and studied in live mice.
Scientists at MD Anderson Cancer Center have engineered a system allowing microscopic monitoring and imaging of cancer in mice, enabling better understanding and treatment of bone metastasis. The model reveals how cancer cells interact with bone and bone resident cells over time, providing insights into the disease's progression.
Medical researchers from MSU propose a new targeted cancer therapy by increasing the activity of wild-type p53, which supports genetic stability and prevents malignant tumor formation. The study reveals that p53 also regulates metastasis formation through various programmed cell death pathways.
A new mouse model has been developed to study bone metastasis, allowing researchers to inject a large number of cancer cells without causing death. The model enables the detection of bone metastasis in the hind limbs with high efficiency and provides insights into cancer cell dormancy and reactivation.
Checkpoint inhibitors have been shown to double median survival and more than double four-year survival rates for patients with melanoma brain metastases. The study analyzed data from over 1,500 cancer programs, revealing a significant improvement in overall survival.
Checkpoint inhibitors improve median and four-year overall survival rates for melanoma brain metastasis patients by 1.4- and 1.5-fold, respectively, according to a national cohort study published in Cancer Immunology Research.
A Phase 1b clinical trial has demonstrated that the combination of tucatinib and T-DM1 can control median 8.2 months in heavily pretreated HER2-positive breast cancer patients, with 48% response rate. The drug also shows efficacy against brain metastases, a major cause of mortality from the disease.
A University of Colorado Cancer Center study found that brain metastases are a common occurrence in stage IV ROS1-positive non-small cell lung cancer. The study also showed that patients with ROS1 mutations had similar progression-free survival rates as ALK patients when treated with crizotinib, but with a higher risk of brain metastas...
Researchers discovered that pancreatic cancer cells' ability to alter their characteristics and shape affects where metastases form. The presence of E-cadherin protein controls this process, with its absence leading to lung metastases but not liver metastases.
A new computational method, MACHINA, has been developed to track the spread of cancer cells from one part of the body to another. The algorithm integrates DNA sequence data with information on where cells are located in the body, yielding a clearer picture of cancer migration histories than previous studies.
A new study finds that enzalutamide significantly lowers the risk of metastasis or death in men with non-metastatic castrate-resistant prostate cancer, delaying cancer re-appearance by almost two years. The drug also shows a 71% lower risk of metastasis or death compared to placebo.
PharmaMar and Chugai agree on an early termination of their license agreement for Zepsyre in Japan, allowing PharmaMar to regain rights to the compound. PharmaMar will receive €3,000,000 from Chugai and can now pursue new partnerships for the drug.